Core Viewpoint - The perception that myopia surgery completely eliminates myopia and prevents regression is incomplete, as myopia cannot be cured, and new myopia may develop if eye care is neglected [1][2] Group 1: Myopia Surgery Insights - Myopia surgery can help individuals become independent from glasses, with techniques such as corneal laser surgery (e.g., SMILE Pro) and intraocular lens surgery (e.g., ICL, V4C, V5) effectively improving vision [1] - Post-surgery, it is crucial to maintain long-term eye care, as improper habits like excessive screen time or rubbing the eyes can still negatively impact vision [1] Group 2: Vision Protection Recommendations - To protect vision, maintaining a regular schedule and avoiding prolonged screen time is essential, with the "20-20" rule recommended: take a 20-second break every 20 minutes of screen time, ideally looking at something 5 meters away [2] - There is currently no medical evidence supporting the effectiveness of myopia prevention patches or devices, and validated methods should be prioritized for myopia control [2] - Recommended strategies for myopia prevention include at least 2 hours of outdoor activity daily, using optical aids like OK lenses or prescription glasses under medical guidance, and considering low-concentration atropine under a doctor's advice [2]

Group 1 - The company emphasizes the importance of market capitalization management and is committed to enhancing communication with the market [1] - The company is implementing various measures to demonstrate confidence, including share buybacks, executive stock purchases, and cash dividends [1] - The company will disclose any further buyback plans in accordance with relevant regulations in a timely manner [1]

智通财经APP讯，朝聚眼科(02219)发布公告，于2025年12月18日，该公司斥资32.69万港元回购12万 股。 ...

格隆汇12月19日丨朝聚眼科(02219.HK)发布公告，2025年12月18日耗资32.69万港元回购12万股，回购 价格每股2.71-2.73港元。 ...

Core Viewpoint - The successful cataract surgery of a prominent public diplomat, Yu Xi, highlights the effectiveness and advancements in modern cataract surgery, emphasizing patient trust and satisfaction in the medical process [1][4]. Group 1: Patient Experience - Yu Xi's vision was significantly impaired before surgery, with a pre-operative vision of approximately 0.3, causing difficulties in daily activities [4]. - The decision to undergo surgery was influenced by the positive experience of a family member who had a successful cataract operation performed by Professor Fu Xun'an 15 years ago [4][6]. - The surgery was performed under local anesthesia, resulting in minimal pain and a quick procedure, which alleviated Yu Xi's initial fears about the surgery [4][6]. Group 2: Medical Professional Insights - Professor Fu Xun'an has over 40 years of experience in ophthalmology, with a strong reputation for his meticulous surgical techniques, particularly in the final steps of cataract surgery [6]. - The surgery's success is attributed to modern minimally invasive techniques, which allow for quick recovery and restoration of clear vision [6]. - Professor Fu emphasizes the importance of early detection and treatment of cataracts to prevent complications and improve quality of life for older adults [6].

Group 1 - The company, Aier Eye Hospital (300015), indicated on its interactive platform that it will disclose any future share repurchase or increase plans in accordance with regulations [1]

Core Viewpoint - The Second Global Ophthalmology Conference 2026 will be held on March 19, 2026, in Beijing, focusing on the integration of medicine and engineering, technological innovation, and clinical value in the ophthalmology industry [1]. Event Overview - The conference will cover various trends in ophthalmology, including imaging, refractive and myopia treatment, innovative therapies, surgical techniques, and preclinical validation [1]. - The event will also open applications for the "2026 Global Ophthalmology Annual Awards" and invite teams to co-author the "Global Ophthalmology Innovation White Paper" [2]. Conference Highlights - The conference will feature the release of the "2026 Global Ophthalmology Innovation White Paper" and the awarding of the "Ophthalmology Innovation Series Awards" to establish industry benchmarks [7]. - There will be premium exhibition spaces for sponsors to engage with high-quality decision-makers, product demonstrations, and collaboration opportunities [7]. - An "Innovation Demo Hour" will allow selected innovative teams to present their projects in 5-10 minute high-density pitches, addressing investment and collaboration needs [14]. Thematic Focus Areas - **Next-Generation Ophthalmic Imaging and AI**: This section will explore the integration of imaging and algorithms, focusing on academic advancements and practical applications [11]. - **Refractive, Vision Care, and Glaucoma**: This segment will address the commercial aspects of refractive surgery and myopia prevention strategies, including optical, pharmaceutical, and behavioral interventions [13]. - **Surgical Innovations**: The conference will showcase next-generation surgical technologies, including robotics and real-time imaging for enhanced precision [13]. - **Device Development and Preclinical Validation**: This area will present the system of "industrial service chains" to assist research and innovation enterprises in resource matching [13]. Participation and Collaboration - The conference aims to attract a diverse audience, including academic teams with recent research outcomes, engineering teams with prototype products, and early-stage innovative companies [16]. - Collaboration opportunities are available for those interested in participating in the conference, with contact details provided for the organizing team [17].

Group 1 - The 2025 International Nystagmus Symposium was held, focusing on the theme "Decoding Nystagmus Mechanisms and Innovating Treatment Pathways," gathering top ophthalmic experts and researchers from Europe, America, and the Asia-Pacific region [1] - The symposium provided a high-level academic exchange platform for discussions on the pathogenesis, diagnostic standards, and treatment innovations related to nystagmus [1] Group 2 - Yang Dongsheng, a leading figure in China's nystagmus treatment field and director of the Visual Rehabilitation Research Institute at Aier Eye Hospital, presented significant research findings at the symposium [4] - Yang's report titled "Nystagmus Reduction Surgery: Effects and Mechanism Explained by Eye Movement Models" highlighted that nystagmus reduction surgery, rather than head position correction surgery, significantly reduces the severity of nystagmus and improves vision, offering a "Chinese solution" for global nystagmus treatment [4] - Yang also participated in the American Nystagmus Network's international symposium in Philadelphia, discussing the latest advancements in nystagmus treatment with 13 top experts from various countries and sharing clinical experiences from thousands of nystagmus patients treated in Changsha [4]

Core Insights - Shenzhen People's Hospital Longhua Branch has been awarded a four-star rating for its "Shenzhen Dry Eye Diagnosis and Treatment Center," marking a significant recognition of its technical capabilities in the field of dry eye treatment [1][2] - The establishment of this center is expected to enhance the quality of care for dry eye patients in the region, addressing a growing public health concern as the prevalence of dry eye in China exceeds 400 million, with a 40% outpatient rate and 58.7% among the 16-30 age group [1][2] Group 1 - The dry eye clinic at the hospital was established in 2019 and has met the four-star standard for dry eye diagnosis and treatment centers, positioning itself as a regional demonstration center [2] - The successful certification of the clinic will focus on the mechanisms of dry eye disease, standardized treatment systems, and scientific evaluation of treatment efficacy, aiming to address current deficiencies in standardized care [2] - The hospital aims to optimize service quality continuously and achieve a five-star rating by 2026 to provide even better care for dry eye patients [2] Group 2 - The hospital's dry eye treatment team is highly qualified, with key members including Dr. Li Qiang, an experienced ophthalmologist specializing in glaucoma and cataracts, and Dr. Zhang Jiajiao, who leads the center and focuses on integrated Chinese and Western medicine for dry eye treatment [2] - The nursing team is led by Li Lin, a senior nurse with 22 years of clinical experience in ophthalmic care, contributing to the overall quality of treatment and patient guidance [2]

Group 1 - The company, Chaoyue Ophthalmology (02219.HK), announced a share buyback plan on December 16, 2025, involving an expenditure of HKD 315,000 to repurchase 120,000 shares [1] - The buyback price range is set between HKD 2.59 and HKD 2.64 per share [1]